JP2016530280A5 - - Google Patents

Download PDF

Info

Publication number
JP2016530280A5
JP2016530280A5 JP2016537902A JP2016537902A JP2016530280A5 JP 2016530280 A5 JP2016530280 A5 JP 2016530280A5 JP 2016537902 A JP2016537902 A JP 2016537902A JP 2016537902 A JP2016537902 A JP 2016537902A JP 2016530280 A5 JP2016530280 A5 JP 2016530280A5
Authority
JP
Japan
Prior art keywords
vegf antibody
glioblastoma
chemotherapeutic agent
patient
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016537902A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016530280A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/053463 external-priority patent/WO2015031782A1/en
Publication of JP2016530280A publication Critical patent/JP2016530280A/ja
Publication of JP2016530280A5 publication Critical patent/JP2016530280A5/ja
Pending legal-status Critical Current

Links

JP2016537902A 2013-08-30 2014-08-29 膠芽腫治療のための併用療法 Pending JP2016530280A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361872165P 2013-08-30 2013-08-30
US61/872,165 2013-08-30
US201462004687P 2014-05-29 2014-05-29
US62/004,687 2014-05-29
PCT/US2014/053463 WO2015031782A1 (en) 2013-08-30 2014-08-29 Combination therapy for the treatment of glioblastoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019204258A Division JP2020059713A (ja) 2013-08-30 2019-11-11 膠芽腫治療のための併用療法

Publications (2)

Publication Number Publication Date
JP2016530280A JP2016530280A (ja) 2016-09-29
JP2016530280A5 true JP2016530280A5 (cg-RX-API-DMAC7.html) 2017-10-12

Family

ID=52584140

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016537902A Pending JP2016530280A (ja) 2013-08-30 2014-08-29 膠芽腫治療のための併用療法
JP2019204258A Pending JP2020059713A (ja) 2013-08-30 2019-11-11 膠芽腫治療のための併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019204258A Pending JP2020059713A (ja) 2013-08-30 2019-11-11 膠芽腫治療のための併用療法

Country Status (14)

Country Link
US (1) US10617755B2 (cg-RX-API-DMAC7.html)
EP (1) EP3038647B1 (cg-RX-API-DMAC7.html)
JP (2) JP2016530280A (cg-RX-API-DMAC7.html)
KR (1) KR20160048095A (cg-RX-API-DMAC7.html)
CN (1) CN105611939A (cg-RX-API-DMAC7.html)
AU (1) AU2014312130B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016004415A2 (cg-RX-API-DMAC7.html)
CA (1) CA2921213A1 (cg-RX-API-DMAC7.html)
HK (1) HK1221408A1 (cg-RX-API-DMAC7.html)
IL (1) IL244014A0 (cg-RX-API-DMAC7.html)
MX (1) MX2016002645A (cg-RX-API-DMAC7.html)
RU (1) RU2692075C2 (cg-RX-API-DMAC7.html)
SG (2) SG10201704334QA (cg-RX-API-DMAC7.html)
WO (1) WO2015031782A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2828739T3 (es) 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US8569348B2 (en) 2009-07-06 2013-10-29 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
US20130095065A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for Treating Vascular Leak Syndrome and Cancer
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
EP3116503A4 (en) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CN106460067A (zh) 2014-07-14 2017-02-22 豪夫迈·罗氏有限公司 诊断方法和用于治疗成胶质细胞瘤的组合物
EP3977994B1 (en) 2015-09-23 2024-04-24 EyePoint Pharmaceuticals, Inc. Activators of tie-2 for use in treating intraocular pressure
JP7088454B2 (ja) 2015-12-30 2022-06-21 コディアック サイエンシーズ インコーポレイテッド 抗体および抗体複合体
EP3463458B1 (en) 2016-06-01 2024-04-10 Celgene Tri A Holdings Ltd. Combined use of marizomib and bevacizumab for the treatment of central nervous system (cns) cancers
SG11201900464TA (en) 2016-07-20 2019-02-27 Aerpio Therapeutics Inc HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
AU2019205279A1 (en) * 2018-01-08 2020-07-30 Susavion Biosciences, Inc. Compositions and methods of treating cancer with glycomimetic peptides
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
SG11202009145PA (en) 2018-03-20 2020-10-29 Abraxis Bioscience Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
CN113189344B (zh) * 2018-07-09 2022-08-19 南京艾蓝生物科技有限公司 Pdlim4用作胃癌标志物的应用
EP3856245A4 (en) 2018-09-24 2022-10-26 EyePoint Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - ß (VE-PTP) AND VEGF
EP3962482A4 (en) 2019-04-29 2023-01-11 EyePoint Pharmaceuticals, Inc. TIE 2 ACTIVATORS FACING THE SCHLEMM CHANNEL
WO2021026685A1 (zh) * 2019-08-09 2021-02-18 安徽瀚海博兴生物技术有限公司 一种新型结构的抗vegf-抗pd1双特异性抗体
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
RU2765112C1 (ru) * 2021-04-15 2022-01-25 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ выбора тактики проведения лучевой терапии у больных злокачественными глиомами

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
IL105914A0 (en) 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
WO1994010202A1 (en) 1992-10-28 1994-05-11 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
EP1695985B1 (en) 1997-04-07 2011-03-09 Genentech, Inc. Methods for forming humanised antibodies by random mutagenesis
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
SI1325932T1 (cg-RX-API-DMAC7.html) 1997-04-07 2005-08-31 Genentech Inc
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
EP1034298B1 (en) 1997-12-05 2011-11-02 The Scripps Research Institute Humanization of murine antibody
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US20030180714A1 (en) 1999-12-15 2003-09-25 Genentech, Inc. Shotgun scanning
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
KR20030074693A (ko) 2000-12-28 2003-09-19 알투스 바이올로직스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
US7226577B2 (en) * 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
EP1585767A2 (en) 2003-01-16 2005-10-19 Genentech, Inc. Synthetic antibody phage libraries
US20050186208A1 (en) 2003-05-30 2005-08-25 Genentech, Inc. Treatment with anti-VEGF antibodies
CA2531595C (en) 2003-07-28 2015-12-08 Genentech, Inc. Reducing protein a leaching during protein a affinity chromatography
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
BRPI0508761A (pt) 2004-03-31 2007-08-14 Genentech Inc anticorpo humanizado, composição que compreende um anticorpo humanizado, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo humanizado, método de tratamento de disfunção tgf-beta, método de detecção de tgf-beta, artigo industrializado e método de tratamento de cáncer
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
EP1973951A2 (en) 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
WO2007111733A2 (en) 2005-12-16 2007-10-04 Genentech, Inc. Method for diagnosing, prognosing and treating glioma
WO2007134050A2 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
EP2132336A1 (en) 2007-03-02 2009-12-16 Board of Regents, The University of Texas System Multigene assay to predict outcome in an individual with glioblastoma
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
BRPI1006438A2 (pt) 2009-04-20 2016-09-27 Genentech Inc terapia adjuvante de cancer
MX2012001716A (es) 2009-08-14 2012-04-02 Genentech Inc Marcadores biologicos para monitorizar la respuesta del paciente a los antagonistas vegf.
AR080244A1 (es) 2010-02-23 2012-03-21 Genentech Inc Terapia anti-angiogenesis para el tratamiento del cancer ovarico
EP4159226A1 (en) 2010-08-24 2023-04-05 University of Pittsburgh - Of the Commonwealth System of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
KR20140044341A (ko) 2011-06-02 2014-04-14 알막 다이아그노스틱스 리미티드 암에 대한 분자적 진단 검사
BR112014017320A2 (pt) 2012-01-13 2018-05-29 Genentech Inc método para determinar se um paciente é propenso a responder ao tratamento com um antagonista de vegf, método para otimizar a eficácia terapêutica de um antagonista de vegf, método para selecionar uma terapia, método para identificar um biomarcador e método para diagnosticar um distúrbio angiogênico
HK1200739A1 (en) 2012-03-30 2015-08-14 霍夫曼-拉罗奇有限公司 Diagnostic methods and compositions for treatment of cancer
BR112015002681A2 (pt) 2012-08-07 2018-08-28 Genentech Inc método para tratar um paciente e kit
WO2014087156A1 (en) 2012-12-03 2014-06-12 Almac Diagnostics Limited Molecular diagnostic test for cancer
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
CN106460067A (zh) 2014-07-14 2017-02-22 豪夫迈·罗氏有限公司 诊断方法和用于治疗成胶质细胞瘤的组合物

Similar Documents

Publication Publication Date Title
JP2016530280A5 (cg-RX-API-DMAC7.html)
RU2016109448A (ru) Комбинированная терапия для лечения глиобластомы
JP2015525798A5 (cg-RX-API-DMAC7.html)
CN106604750B (zh) 治疗骨髓瘤
RU2015104001A (ru) Комбинированная терапия для лечения глиобластомы
JP2017031213A5 (cg-RX-API-DMAC7.html)
JP2016528247A5 (cg-RX-API-DMAC7.html)
RU2017108173A (ru) Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1
JP2016528202A5 (cg-RX-API-DMAC7.html)
JP2014533279A5 (cg-RX-API-DMAC7.html)
JP2017533912A5 (cg-RX-API-DMAC7.html)
WO2013152034A1 (en) Dosage and administration of monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
RU2017132877A (ru) Комбинация антагониста pd-1 и эрибулина для лечения рака
JP2017537105A5 (cg-RX-API-DMAC7.html)
JP2018508516A5 (cg-RX-API-DMAC7.html)
JP2016536352A5 (cg-RX-API-DMAC7.html)
JP2016512564A5 (cg-RX-API-DMAC7.html)
JP2019517549A5 (cg-RX-API-DMAC7.html)
RU2017134443A (ru) Способ лечения с применением традипитанта
FI3463345T3 (fi) Farmaseuttisia yhdistelmiä
JP2019530706A5 (cg-RX-API-DMAC7.html)
FI3511004T3 (fi) Yhdistelmävalmisteita syövän hoitoon
JP2016526531A5 (cg-RX-API-DMAC7.html)
JP2017503014A5 (cg-RX-API-DMAC7.html)
JP2018522028A5 (cg-RX-API-DMAC7.html)